Principal Financial Group Inc. Has $30.11 Million Position in Immunome, Inc. $IMNM

Principal Financial Group Inc. cut its stake in shares of Immunome, Inc. (NASDAQ:IMNM) by 2.0% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,376,867 shares of the company’s stock after selling 27,583 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunome were worth $30,112,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Creative Planning increased its stake in Immunome by 4.0% in the third quarter. Creative Planning now owns 18,664 shares of the company’s stock valued at $219,000 after purchasing an additional 710 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Immunome by 14.4% during the 4th quarter. Russell Investments Group Ltd. now owns 7,417 shares of the company’s stock worth $159,000 after purchasing an additional 935 shares in the last quarter. California State Teachers Retirement System boosted its position in shares of Immunome by 1.8% during the 4th quarter. California State Teachers Retirement System now owns 67,012 shares of the company’s stock worth $1,439,000 after purchasing an additional 1,167 shares in the last quarter. Virtus Investment Advisers LLC grew its stake in shares of Immunome by 16.9% in the 4th quarter. Virtus Investment Advisers LLC now owns 13,593 shares of the company’s stock valued at $292,000 after buying an additional 1,970 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in shares of Immunome by 81.8% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after buying an additional 2,909 shares during the period. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

IMNM has been the topic of a number of research reports. Wedbush reaffirmed an “outperform” rating and set a $31.00 price target on shares of Immunome in a research note on Friday, June 12th. Citigroup reissued a “buy” rating on shares of Immunome in a research note on Thursday, July 9th. Truist Financial boosted their price objective on Immunome from $36.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, May 28th. Barclays started coverage on Immunome in a research report on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Finally, Wall Street Zen cut Immunome from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. Thirteen research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $33.17.

Insider Buying and Selling at Immunome

In other news, CFO Max Rosett sold 60,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $18.23, for a total value of $1,093,800.00. Following the transaction, the chief financial officer owned 54,037 shares in the company, valued at $985,094.51. This trade represents a 52.61% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jean Jacques Bienaime bought 10,500 shares of the company’s stock in a transaction dated Friday, June 5th. The stock was bought at an average price of $19.45 per share, for a total transaction of $204,225.00. Following the acquisition, the director directly owned 43,415 shares of the company’s stock, valued at approximately $844,421.75. This represents a 31.90% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 472,142 shares of company stock worth $10,262,648. 7.21% of the stock is currently owned by corporate insiders.

Immunome Price Performance

Shares of NASDAQ IMNM opened at $22.32 on Monday. The stock has a market capitalization of $2.53 billion, a P/E ratio of -9.38 and a beta of 2.07. The company has a 50-day moving average price of $21.00 and a 200-day moving average price of $21.91. Immunome, Inc. has a 1 year low of $8.66 and a 1 year high of $27.65.

Immunome (NASDAQ:IMNM) last posted its earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities research analysts anticipate that Immunome, Inc. will post -2.06 earnings per share for the current fiscal year.

Immunome Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.